Reframing the Debate on Abortion Drugs in an Era of Misinformation
DOI:
https://doi.org/10.63501/a62q4316Keywords:
Abortion, Medical Abortion, Mifepristone, Misoprostol, Mifeprex, RU-486, CytotecAbstract
N/A
References
American College of Obstetricians and Gynecologists. (2020). Medication abortion up to 70 days of gestation (Practice Bulletin No. 225). https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2020/10/medication-abortion-up-to-70-days-of-gestation
Zhang J, Zhou K, Shan D, Luo X. Medical methods for first-trimester abortion. Cochrane Database of Systematic Reviews 2022, Issue 5. Art. No.: CD002855. https://doi.org/10.1002/14651858.CD002855.pub5
Endler, M., Lavelanet, A., Cleeve, A., Ganatra, B., Gomperts, R., & Gemzell-Danielsson, K. (2019). Telemedicine for medical abortion: A systematic review. BJOG: An International Journal of Obstetrics & Gynecology, 126(9), 1094–1102. https://doi.org/10.1111/1471-0528.15684
Jung, C., Oviedo, J., & Nippita, S. (2023). Abortion care in the United States: Current evidence and future directions. NEJM Evidence, 2(4), EVIDra2200300. https://doi.org/10.1056/EVIDra2200300
World Health Organization. (2022). Abortion care guideline. https://www.who.int/publications/i/item/9789240039483
Downloads
Published
Issue
Section
License
This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, provided appropriate credit is given to the author(s) and the source. To view a copy of this license, visit: https://creativecommons.org/licenses/by/4.0